Search results for Eli Lilly

<![CDATA[Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics ]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics]]>

<![CDATA[Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics ]]>

<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>

<![CDATA[Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion ]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio]]>

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Eli Lilly to Acquire Kelonia Therapeutics

On April 20, 2026, Eli Lilly & Company (“Lilly”) and Kelonia Therapeutics, Inc. (“Kelonia”) announced an agreement for Lilly to acquire Kelonia in an all-cash transaction expec...

This Drug Stock Has Crushed the S&P 500 Over the Last Decade

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

Trung Huynh, an analyst with RBC Capital Markets, has projected Foundayo will reach peak-year sales of $36 billion—14% above the $31.68 billion racked up by last year’s best sellin...

Jim Cramer Praises Eli Lilly’s Performance

<![CDATA[Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request ]]>

Eli Lilly and Company 2026 Q1 - Results - Earnings Call Presentation

AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years

Eli Lilly & Co. CEO David Ricks on Tuesday said the company is investing heavily in artificial intelligence as well as follow-ons to its early weight-loss drugs.

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. 

Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.

Here’s What the Street is Saying About Eli Lilly and Company (LLY)

Lilly Dermatology Division?

Lilly Dermatology Division? Anonymous (not verified) Sun, 04/26/2026 - 11:14 field_thread_url https://cafepharma.com/boards/threads/lilly-dermatology-divis...

Lilly to buy startup Ajax in bid for a better JAK drug

Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.

Lilly Dermatology Division?

Lilly Dermatology Division? Anonymous (not verified) Tue, 04/21/2026 - 08:11 field_thread_url https://cafepharma.com/boards/threads/lilly-dermatology-divis...

May 26 2026 - Lilly to acquire three vaccine developers for nearly $4 billion

May 26 2026 - Lilly to acquire three vaccine developers for nearly $4 billion admin Tue, 05/26/2026 - 11:55 Lilly keeps pushing forward with deals and pipeline mome...

Great News for Eli Lilly Stock Investors!

The weight loss segment is poised to generate lucrative profits for Eli Lilly.

CEO Of Lilly: It’s About Profits

CEO Of Lilly: It’s About Profits Anonymous (not verified) Thu, 04/02/2026 - 16:59 pharmagather item url CEO Of Lilly: It’s About Profits...

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

The U.S. Food & Drug Administration just approved Eli Lilly's GLP-1 pill orforglipron.